-
Tytuł:
-
Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET.
-
Autorzy:
-
Sobic Saranovic DP; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia; Center for Nuclear Medicine, Clinical Center of Serbia, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
Nikitovic M; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia; National Cancer Research Center, Pasterova 14, 11000, Belgrade, Serbia. Electronic address: .
Saponjski J; Center for Nuclear Medicine, Clinical Center of Serbia, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
Grozdic Milojevic I; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia; Center for Nuclear Medicine, Clinical Center of Serbia, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
Paripovic L; National Cancer Research Center, Pasterova 14, 11000, Belgrade, Serbia. Electronic address: .
Saranovic D; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
Beatovic S; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia; Center for Nuclear Medicine, Clinical Center of Serbia, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
Artiko VM; Faculty of Medicine, University of Belgrade, Visegradska 26 St., 11000, Belgrade, Serbia; Center for Nuclear Medicine, Clinical Center of Serbia, Visegradska 26 St., 11000, Belgrade, Serbia. Electronic address: .
-
Źródło:
-
European journal of radiology [Eur J Radiol] 2020 Aug; Vol. 129, pp. 109076. Date of Electronic Publication: 2020 May 16.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Limerick : Elsevier Science Ireland Ltd
Original Publication: Stuttgart ; New York : Thieme, [c1981-
-
MeSH Terms:
-
Fluorodeoxyglucose F18*
Bone Neoplasms/*diagnostic imaging
Neuroectodermal Tumors, Primitive/*diagnostic imaging
Positron Emission Tomography Computed Tomography/*methods
Sarcoma, Ewing/*diagnostic imaging
Adolescent ; Adult ; Bone Neoplasms/mortality ; Child ; Child, Preschool ; Cohort Studies ; Disease Progression ; Female ; Humans ; Male ; Neuroectodermal Tumors, Primitive/mortality ; Predictive Value of Tests ; Progression-Free Survival ; Radiopharmaceuticals ; Reproducibility of Results ; Retrospective Studies ; Sarcoma, Ewing/mortality ; Sensitivity and Specificity ; Treatment Outcome ; Young Adult
-
Contributed Indexing:
-
Keywords: Ewing sarcoma and PNET; F-18 FDG PET/CT; Follow-up; Metastatic disease; Progression-free survival; Recurrence
-
Substance Nomenclature:
-
0 (Radiopharmaceuticals)
0Z5B2CJX4D (Fluorodeoxyglucose F18)
-
Entry Date(s):
-
Date Created: 20200524 Date Completed: 20210114 Latest Revision: 20210114
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.ejrad.2020.109076
-
PMID:
-
32446127
-
Purpose: To determine if post-treatment F-18 FDG PET/CT results (overall positive findings, specific localizations) are independent predictors of disease progression in young patients with Ewing sarcoma and Primitive neuroectodermal tumor.
Method: A consecutive sample of 48 patients (age 14 ± 5 years, 32 male) was referred to F-18 FDG PET/CT for the suspected progression of Ewing sarcoma (39 patients) and Primitive neuroectodermal tumor (PNET) (9 patients) and followed-up clinically for 4.3 ± 2.3 years after F-18 FDG PET/CT (range 1-8 years). The diagnostic value of F-18 FDG PET/CT was determined in comparison to the biopsy. Kaplan-Meier analysis was used to compare progression-free survival between the groups with positive and negative F-18 FDG PET/CT findings. Variables included in the Cox regression for predicting the progression-free survival were sex, age, F-18 FDG PET/CT findings, MDCT findings, and MR ratio.
Results: F-18 FDG PET/CT findings were positive in 32 (67 %) patients (sensitivity 93.7 %, specificity 87.5 %, accuracy 91.7 %) with an average SUVmax of 5.8 ± 3.2 (95 % CI 4.8-7.1). The progression-free survival was significantly lower (p = 0.001) in patients with positive F-18 FDG PET/CT findings (median 28 months) and when recurrence was located in bones, soft tissues, and muscles (p = 0.02, median 21 months). The significant predictors of the disease progression were the overall positive F-18 FDG PET/CT findings (HR 8.36, p = 0.004) and, specifically, the local recurrence in the bone with infiltration of soft tissue/muscles (HR 4.08, p = 0.003).
Conclusion: Post-treatment F-18 FDG PET/CT findings are useful for predicting the progression of Ewing sarcoma and PNET and should be included in the clinical monitoring of these patients.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
